Recombinant chicken mycoplasma synoviae antigen protein as well as coding gene, preparation method and application thereof

By developing recombinant mycoplasma antigen protein and polyclonal antibodies for chicken synovial fluid, the lack of neutralization activity and antibiotic resistance in existing vaccines has been solved, and effective prevention and control and economic protection effects on multiple pathogens have been achieved.

CN119060145AActive Publication Date: 2024-12-03YANGZHOU UNIV

Patent Information

Application Number
CN202411199916.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-03
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

The existing mycoplasma chicken synovialis vaccine lacks neutralizing active antigen protein, making it difficult to effectively prevent and control multiple variants of the pathogen. The use of antibiotics leads to increased drug resistance, difficulty in spreading, increased economic losses and food safety risks.

Method used

The recombinant mycoplasma antigen protein of chicken synovial fluid was developed. Through the construction of encoding genes and expression vectors, the E. coli expression system was used to express proteins with neutralizing and protective activity, and polyclonal antibodies and vaccines were prepared for prevention and treatment of chicken synovial fluid. Mycoplasma cystic infection.

Benefits of technology

It provides a significant growth inhibitory effect on Mycoplasma of the synovialis of chicken, with a neutralizing antibody titer of more than 1:256, which has the potential of subunit vaccines, significantly reducing the difficulty of prevention and control and economic losses of Mycoplasma of the chiffinialis of the chiffinialis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060145A_ABST
    Figure CN119060145A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant chicken mycoplasma synoviae antigen protein as well as a coding gene, a preparation method and application thereof. A prokaryotic expression system is used for expressing and purifying rRS02775 recombinant protein, rRS01455 recombinant protein, rRS01745 recombinant protein, rRS01040 recombinant protein, rRS01750 recombinant protein and rRS02145 recombinant protein respectively, further, the multi-antibody serum prepared by immunizing BALB / c mice has a remarkable growth inhibition effect on a chicken mycoplasma synoviae WVU1853 strain, a Ningxia / 2017-1 strain and a Shandong / 2017-2 strain, the highest valence of a neutralizing antibody can reach 1: 256, and the multi-antibody serum has the potential of being used for developing chicken mycoplasma synoviae subunit vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedical technology, and in particular relates to a recombinant chicken synoviae mycoplasma antigen protein, a coding gene thereof, a preparation method and an application thereof. Background Art

[0002] Mycoplasma synoviae (MS) can cause synovitis, air sac inflammation, eggshell apex abnormality (EAA) in chickens, which can lead to reduced feed return, growth retardation, increased culling rate and reduced egg production, resulting in huge economic losses. MS can also present mixed infections with other pathogens, leading to more severe clinical symptoms and higher mortality.

[0003] Control of Mycoplasma synoviae infection mainly includes: purification of breeder flocks, drug prevention and treatment, and vaccination. Mycoplasma synoviae can be transmitted both horizontally and vertically, and purification of breeder flocks is economically costly and difficult. The abuse of antibiotics can significantly enhance their drug resistance and increase food safety risks. Currently, the vaccine products used to prevent and control Mycoplasma synoviae mainly include attenuated live vaccines and inactivated vaccines. There is no commercialized Mycoplasma synoviae subunit vaccine.

[0004] Neutralizing antigens are antigens that can induce neutralizing antibodies against pathogens and play an important role in inducing immune protection, immune evaluation and vaccine design. So far, there has been no report on chicken synoviae protein with neutralizing activity. Summary of the invention

[0005] Purpose of the invention: The technical problem to be solved by the present invention is to provide a recombinant chicken synoviae Mycoplasma antigen protein with immune neutralization and protective activity.

[0006] The technical problem that the present invention also aims to solve is to provide a nucleic acid or gene encoding the recombinant chicken synoviae Mycoplasma antigen protein.

[0007] The technical problem that the present invention also aims to solve is to provide an expression cassette, a recombinant vector or a recombinant bacterium containing the nucleic acid or gene.

[0008] The technical problem that the present invention also aims to solve is to provide a method for preparing the recombinant chicken synoviae Mycoplasma antigen protein.

[0009] The technical problem that the present invention also aims to solve is to provide the use of the recombinant chicken synoviae Mycoplasma antigen protein, the nucleic acid or gene, the expression cassette, the recombinant vector and the recombinant bacteria in the preparation of drugs, polyclonal antibodies or vaccines for treating or preventing chicken synoviae Mycoplasma infection.

[0010] The technical problem that the present invention needs to solve is to provide a polyclonal antibody.

[0011] The final technical problem to be solved by the present invention is to provide a vaccine.

[0012] Technical solution: In order to solve the above technical problems, the present invention provides a recombinant chicken synoviae Mycoplasma antigen protein, selected from the following proteins (a), (b) or (c):

[0013] (a) a protein with an amino acid sequence as shown in SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, or SEQ ID NO:38,

[0014] (b) a protein derived from (a) in which the amino acid sequence in (a) is substituted, deleted or added with one or more amino acids and has the activity of an antigenic protein of Mycoplasma synoviae;

[0015] (c) a protein having an amino acid sequence as shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12.

[0016] The present invention also includes a nucleic acid or gene encoding the recombinant chicken synoviae Mycoplasma antigen protein, wherein the nucleic acid or gene is selected from the following genes or nucleic acids (i), (ii) or (iii):

[0017] (i) a gene or nucleic acid whose nucleotide sequence is shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11;

[0018] (ii) a gene or nucleic acid having the activity of encoding an antigenic protein of Mycoplasma synoviae in which the nucleotide sequence in (i) is substituted, deleted or added with one or more bases;

[0019] (iii) a gene or nucleic acid having a nucleotide sequence as shown in SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 or SEQ ID NO:32.

[0020] Among them, as a preference, the recombinant chicken synoviae Mycoplasma antigen protein includes rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 or rRS02145, and the corresponding amino acid sequences are shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12, respectively.

[0021] The present invention also includes an expression cassette, a recombinant vector or a recombinant bacterium, which contains the nucleic acid or gene.

[0022] The recombinant vector is obtained by inserting the nucleic acid or gene into a vector. Preferably, the nucleic acid or gene is inserted between the T7 terminator sequence and the lac operator sequence of the vector.

[0023] Wherein, the vector includes but is not limited to a prokaryotic expression vector.

[0024] Preferably, the prokaryotic expression vector includes but is not limited to an Escherichia coli expression vector, and the Escherichia coli expression vector includes but is not limited to pET-32a.

[0025] Wherein, the nucleic acid or gene comprises a gene encoding the Mycoplasma synoviae RS02775 protein, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 1 obtained by codon optimization;

[0026] Wherein, the nucleic acid or gene comprises a gene encoding the Mycoplasma synoviae RS01455 protein, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 3 obtained by codon optimization;

[0027] Wherein, the nucleic acid or gene comprises a gene encoding the Mycoplasma synoviae RS01745 protein, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 5 obtained by codon optimization;

[0028] Wherein, the nucleic acid or gene comprises a gene encoding the Mycoplasma synoviae RS01040 protein, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 7 obtained by codon optimization;

[0029] Wherein, the nucleic acid or gene comprises a gene encoding a Mycoplasma synoviae RS01750 protein, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 9 obtained by codon optimization;

[0030] Wherein, the nucleic acid or gene comprises a gene encoding the RS02145 protein of Mycoplasma synoviae, and the nucleic acid or gene sequence is the sequence shown in SEQ ID NO: 11 obtained by codon optimization.

[0031] Preferably, the 3′ end of the Mycoplasma synoviae RS02775 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS02775 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0032] Preferably, the 3′ end of the Mycoplasma synoviae RS01455 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS01455 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0033] Preferably, the 3′ end of the Mycoplasma synoviae RS01745 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS01745 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0034] Preferably, the 3′ end of the Mycoplasma synoviae RS01040 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS01040 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0035] Preferably, the 3′ end of the Mycoplasma synoviae RS01750 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS01750 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0036] Preferably, the 3′ end of the Mycoplasma synoviae RS02145 protein encoding gene is connected to a 6×His tag peptide sequence, and the 5′ end is sequentially connected to an S-Tag tag peptide sequence, a 6×His tag peptide sequence, and a TrxA tag peptide sequence. The recombinant expression vector is a pET-32a-RS02145 vector in which a target gene fragment is inserted between a T7 terminator sequence and a lac operator sequence.

[0037] The present invention also includes a method for preparing the recombinant chicken synoviae Mycoplasma antigen protein, comprising the following steps:

[0038] 1) obtaining the nucleic acid or gene;

[0039] 2) introducing the nucleic acid or gene obtained in step 1) into a vector to obtain a recombinant vector;

[0040] 3) The recombinant vector is introduced into the host bacteria to induce expression to obtain the recombinant chicken synoviae Mycoplasma antigen protein.

[0041] The step of obtaining the nucleic acid or gene in step 1) comprises: referring to the RS02775 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence of positions 591671 to 593977 of CP083748.1 published by GenBank, the RS01455 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence of positions 203259 to 205574 of CP034544.1, and the RS01745 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence of positions 370710 to 372185 of CP083748.1. The gene sequence, the RS01040 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence at positions 311556 to 314174 of CP163310.1, the RS01750 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence at positions 147506 to 149740 of CP163310.1 and the RS02145 gene sequence of Mycoplasma gallinarum shown in the nucleotide sequence at positions 445670 to 447094 of CP083748.1 were overlapped according to the codon bias of Escherichia coli. PCR point mutations were performed on RS02775, RS01455, RS01745, RS01040, RS01750, and RS02145 sequences, and the stop codon TGA in the sequence was mutated to TGG. The sequence of RS02775 after the mutation is shown in SEQ ID NO:1, the sequence of RS01455 after the mutation is shown in SEQ ID NO:3, the sequence of RS01745 after the mutation is shown in SEQ ID NO:5, the sequence of RS01040 after the mutation is shown in SEQ ID NO:7, the sequence of RS01750 after the mutation is shown in SEQ ID NO:9, and the sequence of RS02145 after the mutation is shown in SEQ ID NO:11.

[0042] The specific steps in step 2) include: respectively enzymatically connecting the target gene optimized in step 1) to the pET-32a vector, transforming the ligation product into Trans-T1 competent cells, spreading it on an LB plate containing ampicillin resistance, culturing at 37° C. for 12 to 16 hours, picking single colonies and inoculating them into LB culture medium, identifying the recombinant plasmids by PCR and sequencing, and the recombinant plasmids were named pET-32a-RS02775, pET-32a-RS01455, pET-32a-RS01745, pET-32a-RS01040, pET-32a-RS01750 or pET-32a-RS02145.

[0043] The specific steps in step 3) include: transforming the constructed recombinant plasmids into Escherichia coli BL21 (DE3), identifying positive strains by PCR, and using ITPG to induce positive strains to express rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 or rRS02145 recombinant proteins.

[0044] The present invention also includes a method for purifying recombinant chicken synoviae mycoplasma antigen protein, which is to purify rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 and rRS02145 recombinant proteins by affinity chromatography to obtain corresponding purified recombinant proteins.

[0045] The present invention also includes the use of the recombinant chicken synoviae Mycoplasma antigen protein, the nucleic acid or gene, the expression cassette, the recombinant vector or the recombinant bacteria in the preparation of drugs, polyclonal antibodies or vaccines for treating or preventing chicken synoviae Mycoplasma infection.

[0046] The present invention also includes a polyclonal antibody, which is obtained by immunizing an animal with the recombinant chicken synoviae Mycoplasma antigen protein.

[0047] Preferably, the polyclonal antibody is a neutralizing protective antibody, which comprises respectively mixing purified rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 recombinant proteins with Freund's adjuvant, and can induce the body to produce neutralizing protective antibodies against chicken synoviae Mycoplasma WVU1853 strain, Ningxia / 2017-1 strain, and Shandong / 2017-2 strain.

[0048] The present invention also includes a vaccine, which includes the recombinant chicken synoviae Mycoplasma antigen protein.

[0049] Wherein, the vaccine also includes an adjuvant.

[0050] Preferably, the recombinant chicken synoviae Mycoplasma antigen proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 with immune neutralization and protection activity provided by the present invention can be used to prepare chicken synoviae Mycoplasma subunit vaccines.

[0051] Specifically, the purified recombinant chicken synoviae Mycoplasma antigen proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 and rRS02145 with immune neutralization and protective activity were mixed so that each milliliter of volume contained 111.1 μg of each rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 and rRS02145 recombinant protein, and an appropriate amount of aluminum hydroxide gel adjuvant was added so that the volume ratio of the adjuvant phase to the protein phase was 1:3, so that the final concentration of each protein in the vaccine was 83.3 μg / ml.

[0052] Invention mechanism: The present invention provides six recombinant chicken synoviae Mycoplasma antigen proteins with immune neutralization and protection effects, which are respectively screened out based on the reverse vaccinology method. The chicken synoviae Mycoplasma RS02775, RS01455, RS01745, RS01040, RS01750, RS02145 proteins are then expressed by a prokaryotic expression system. The polyclonal antibodies induced by the recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, rRS02145 have a neutralizing effect on multiple strains of chicken synoviae Mycoplasma.

[0053] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: the polyantiserum prepared by immunization with the rRS02775, rRS01455, rRS01745, rRS01040, rRS01750 and rRS02145 recombinant proteins of the present invention has a significant growth inhibitory effect on the WVU1853 strain, Ningxia / 2017-1 strain and Shandong / 2017-2 strain of Mycoplasma synoviae, and the neutralizing antibody titer can reach above 1:256. It has the potential to be used for the development of subunit vaccines of Mycoplasma synoviae, provides candidate antigens for the development of subunit vaccines of Mycoplasma synoviae, and is of great significance for the prevention and control of Mycoplasma synoviae. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 The gel electrophoresis results of overlap PCR amplification products of RS02775, RS01455, RS01745, RS01040, RS01750, and RS02145 genes;

[0055] Figure 2Gel electrophoresis results of PCR amplification products of colony samples transformed with RS02775, RS01455, RS01745, RS01040, RS01750, and RS02145 genes;

[0056] Figure 3 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS02775;

[0057] Figure 4 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS01455;

[0058] Figure 5 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS01745;

[0059] Figure 6 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS01040;

[0060] Figure 7 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS01750;

[0061] Figure 8 The map of the constructed recombinant prokaryotic expression vector pET-32a-RS02145;

[0062] Fig. 9 The results of SDS-PAGE identification of the recombinant rRS02775 protein expressed in E. coli;

[0063] Fig.10 The results of SDS-PAGE identification of the recombinant rRS01455 protein expressed in E. coli;

[0064] Fig.11 The results of SDS-PAGE identification of the recombinant rRS01745 protein expressed in E. coli;

[0065] Fig.12 The results of SDS-PAGE identification of the recombinant rRS01040 protein expressed in E. coli;

[0066] Fig.13 The results of SDS-PAGE identification of the recombinant rRS01750 protein expressed in E. coli;

[0067] Fig.14 The results of SDS-PAGE identification of the recombinant rRS02145 protein expressed in E. coli;

[0068] Fig.15The identification results of the purified rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 recombinant proteins;

[0069] Fig.16 This is the result of Western blot identification of recombinant protein rRS02775 with polyclonal antibody;

[0070] Fig.17 This is the result of Western blot identification of recombinant protein rRS01455 with polyclonal antibody;

[0071] Fig.18 This is the result of Western blot identification of recombinant protein rRS01745 with polyclonal antibody;

[0072] Fig.19 This is the result of Western blot identification of recombinant protein rRS01040 with polyclonal antiserum;

[0073] Fig. 20 This is the result of Western blot identification of recombinant protein rRS01750 with polyclonal antiserum;

[0074] Fig.21 This is the result of Western blot identification of recombinant protein rRS02145 with polyclonal antibody;

[0075] Fig. 22 Scoring results of chicken paw pads and joint lesions in each group after immunization with a single protein

[0076] Fig.23 Scoring results of chicken paw pads and joint lesions in each group after using the subunit vaccine of the present invention

[0077] Fig.24 The figures are the comparison results of the lesions of the chicken paw pad and tarsal joint in each group after using the subunit vaccine of the present invention. DETAILED DESCRIPTION

[0078] The following detailed and comprehensive description of the embodiments of the present invention is provided in conjunction with specific examples. Obviously, the described examples are only intended to illustrate a part of the embodiments of the present invention and should not be considered as limiting the scope of the present invention. In the examples, the specific conditions not particularly specified are carried out according to the conditions of normal conditions or manufacturer recommendations. The reagents or instruments used are not indicated by the manufacturer and are all commercially available conventional products.

[0079] Example 1 Construction and identification of expression vector pET-32a-RS02775

[0080] 1. RS02775 gene amplification and recovery Referring to the nucleotide sequence of positions 591671 to 593977 of Mycoplasma synoviae strain 5-9 (GenBank No. CP083748.1), the RS02775 gene sequence was mutated by overlap PCR method according to the codon preference of Escherichia coli, and the mutated gene sequence is shown in SEQ ID NO: 1. The amino acid sequence translated from SEQ ID NO: 1 is 100% identical to the amino acid sequence translated from the nucleotide sequence of positions 591671 to 593977 of CP083748.1, both of which are the amino acid sequences shown in SEQ ID NO: 33. The optimized RS02775 gene sequence was used as a template, and RS02775F and RS02775 R were used as upstream and downstream primers (RS02775 F and RS02775 R primer sequences are shown in SEQ ID NO: 13 and SEQ ID NO: 14), respectively. PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (DyePlus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 1:

[0081] Table 1 RS02775 gene amplification system and reaction procedure

[0082]

[0083] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 2325 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery purification kit.

[0084] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Xho I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0085] 3. Enzyme digestion and recovery of RS02775 gene fragment: The recovered and purified RS02775 gene fragment was double-digested with BamH I and Xho I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0086] 4. Ligation: Use T4 DNA ligase to connect the purified and recovered RS02775 gene fragment with the pET-32a plasmid fragment.

[0087] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0088] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers to perform bacterial solution PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. The sample with a band of 2475bp is a positive sample. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the plasmids and corresponding bacterial solutions with correct sequencing were selected for preservation. The correct recombinant vector pET-32a-RS02775 was constructed as shown in the schematic diagram of the vector map. Figure 3 The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO: 2, and the corresponding gene sequence is shown in SEQ ID NO: 27.

[0089] Example 2 Construction and identification of expression vector pET-32a-RS01455

[0090] 1. Amplification and recovery of RS01455 gene Referring to the nucleotide sequence of positions 203259 to 205574 of Mycoplasma synoviae HN01 strain (GenBank No. CP034544.1), the RS01455 gene sequence was mutated by overlap PCR method according to the codon preference of Escherichia coli, and the mutated gene sequence is shown in SEQ ID NO: 3. The amino acid sequence translated from SEQ ID NO: 3 is 100% identical to the amino acid sequence translated from the nucleotide sequence of positions 203259 to 205574 of CP034544.1, both of which are the amino acid sequences shown in SEQ ID NO: 34. The optimized RS01455 gene sequence was used as a template, RS01455F and RS01455 R were used as upstream and downstream primers (RS01455 F and RS01455 R primer sequences are shown in SEQ ID NO: 15 and SEQ ID NO: 16), and PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (Dye Plus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 2:

[0091] Table 2 RS01455 gene amplification system and reaction procedure

[0092]

[0093] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 2334 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery and purification kit.

[0094] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Sal I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0095] 3. Enzyme digestion and recovery of RS01455 gene fragment: The recovered and purified RS01455 gene fragment was double-digested with BamH I and Sal I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0096] 4. Ligation: Use T4 DNA ligase to connect the purified RS01455 gene fragment with the pET-32a plasmid fragment.

[0097] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0098] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers to perform colony PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. Samples with a band of 2505bp are positive samples. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the plasmids and corresponding bacterial solutions with correct sequencing were selected for preservation. The correct recombinant vector pET-32a-RS01455 was constructed as shown in the following figure. Figure 4 The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO:4, and the corresponding gene sequence is shown in SEQ ID NO:28.

[0099] Example 3 Construction and identification of expression vector pET-32a-RS01745

[0100] 1. Amplification and recovery of RS01745 gene Referring to the nucleotide sequence of positions 370710 to 372185 of Mycoplasma synoviae strain 5-9 (GenBank No. CP083748.1), the RS01745 gene sequence was mutated by overlap PCR method according to the codon preference of Escherichia coli, and the gene sequence after mutation is shown in SEQ ID NO: 5. The amino acid sequence translated from SEQ ID NO: 5 has 100% identity with the amino acid sequence translated from the nucleotide sequence of positions 370710 to 372185 of CP083748.1, both of which are the amino acid sequences shown in SEQ ID NO: 35. The optimized RS01745 gene sequence was used as a template, RS01745 F and RS01745 R were used as upstream and downstream primers (RS01745 F and RS01745 R primer sequences are shown in SEQ ID NO: 17 and SEQ ID NO: 18), and PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (Dye Plus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 3:

[0101] Table 3 RS01745 gene amplification system and reaction procedure

[0102]

[0103] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 1494 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery and purification kit.

[0104] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Xho I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0105] 3. Enzyme digestion and recovery of RS01745 gene fragment: The recovered and purified RS01745 gene fragment was double-digested with BamH I and Xho I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0106] 4. Ligation: Use T4 DNA ligase to connect the purified RS01745 gene fragment with the pET-32a plasmid fragment.

[0107] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0108] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers to perform colony PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. The sample with a band of 1644bp is a positive sample. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the plasmids and corresponding bacterial solutions with correct sequencing were selected for preservation. The correct recombinant vector pET-32a-RS01745 was constructed as shown in the schematic diagram of the vector map. Figure 5 The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO:6, and the corresponding gene sequence is shown in SEQ ID NO:29.

[0109] Example 4 Construction and identification of expression vector pET-32a-RS01040

[0110] 1. Amplification and recovery of RS01040 gene Referring to the nucleotide sequence at positions 311556 to 314174 of Mycoplasma synoviae HB01 strain (GenBank No. CP163310.1), the RS01040 gene sequence was mutated by overlap PCR method according to the codon preference of Escherichia coli, and the mutated gene sequence is shown in SEQ ID NO: 7. The amino acid sequence translated from SEQ ID NO: 7 is 100% identical to the amino acid sequence translated from the nucleotide sequence at positions 311556 to 314174 of CP163310.1, both of which are the amino acid sequences shown in SEQ ID NO: 36. The optimized RS01040 gene sequence was used as a template, RS01040F and RS01040 R were used as upstream and downstream primers (RS01040 F and RS01040 R primer sequences are shown in SEQ ID NO: 19 and SEQ ID NO: 20), and PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (Dye Plus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 4:

[0111] Table 4 RS01040 gene amplification system and reaction procedure

[0112]

[0113]

[0114] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 2637 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery and purification kit.

[0115] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Xho I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0116] 3. Enzyme digestion and recovery of RS01040 gene fragment: The recovered and purified RS01040 gene fragment was double-digested with BamH I and Xho I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0117] 4. Ligation: Use T4 DNA ligase to connect the purified RS01040 gene fragment with the pET-32a plasmid fragment.

[0118] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0119] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers for colony PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. The sample with a band of 2787bp is a positive sample. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the plasmids and corresponding bacterial solutions with correct sequencing were selected for preservation. The correct recombinant vector pET-32a-RS01040 was constructed as shown in the schematic diagram of the vector map. Figure 6The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO:8, and the corresponding gene sequence is shown in SEQ ID NO:30.

[0120] Example 5 Construction and identification of expression vector pET-32a-RS01750

[0121] 1. Amplification and recovery of RS01750 gene With reference to the nucleotide sequence at positions 147506 to 149740 of Mycoplasma synoviae HB01 strain (GenBank No. CP163310.1), the RS01750 gene sequence was mutated by overlap PCR method according to the codon preference of Escherichia coli, and the mutated gene sequence is shown in SEQ ID NO: 9. The amino acid sequence translated from SEQ ID NO: 9 is 100% identical to the amino acid sequence translated from the nucleotide sequence at positions 147506 to 149740 of CP163310.1, both of which are the amino acid sequences shown in SEQ ID NO: 37. The optimized RS01750 gene sequence was used as a template, RS01750F and RS01750 R were used as upstream and downstream primers (RS01750 F and RS01750 R primer sequences are shown in SEQ ID NO: 21 and SEQ ID NO: 22), and PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (Dye Plus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 5:

[0122] Table 5 RS01750 gene amplification system and reaction procedure

[0123]

[0124] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 2253 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery purification kit.

[0125] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Xho I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0126] 3. Enzyme digestion and recovery of RS01750 gene fragment: The recovered and purified RS01750 gene fragment was double-digested with BamH I and Xho I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0127] 4. Ligation: Use T4 DNA ligase to connect the purified RS01750 gene fragment with the pET-32a plasmid fragment.

[0128] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0129] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers for colony PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. The sample with a band of 2403bp is a positive sample. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the plasmids and corresponding bacterial solutions with correct sequencing were selected for preservation. The correct recombinant vector pET-32a-RS01750 was constructed as shown in the schematic diagram of the vector map. Figure 7 The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO: 10, and the corresponding gene sequence is shown in SEQ ID NO: 31.

[0130] Example 6 Construction and identification of expression vector pET-32a-RS02145

[0131] 1. RS02145 gene amplification and recovery The RS02145 gene sequence was optimized by overlap PCR method according to the codon preference of Escherichia coli with reference to the nucleotide sequence at positions 445670 to 447094 of Mycoplasma synoviae strain 5-9 (GenBank No. CP083748.1), and the optimized gene sequence is shown in SEQ ID NO: 11. The amino acid sequence translated from SEQ ID NO: 11 is 100% identical to the amino acid sequence translated from the nucleotide sequence at positions 445670 to 447094 of CP083748.1, both of which are the amino acid sequences shown in SEQ ID NO: 38. The optimized RS02145 gene sequence was used as a template, RS02145F and RS02145 R were used as upstream and downstream primers (RS02145 F and RS02145 R primer sequences are shown in SEQ ID NO: 23 and SEQ ID NO: 24), and PCR amplification was performed according to the instructions of 2×Phanta Max Master Mix (Dye Plus) of Nanjing Novozyme Biotechnology Co., Ltd. The amplification system and reaction procedure are shown in Table 6:

[0132] Table 6 RS02145 gene amplification system and reaction procedure

[0133]

[0134] The PCR amplification products were detected by 1% agarose gel electrophoresis. The target gene size was Figure 1 As shown, the target band appeared at the 1443 bp position, indicating that the target gene was amplified successfully and was recovered and purified using a gel recovery purification kit.

[0135] 2. Enzyme digestion and recovery of pET-32a vector: The extracted pET-32a plasmid was double-digested with BamH I and Xho I restriction endonucleases, the digestion products were subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0136] 3. Enzyme digestion and recovery of RS02145 gene fragment: The recovered and purified RS02145 gene fragment was double-digested with BamH I and Xho I restriction endonucleases, the digestion product was subjected to gel electrophoresis, and recovered and purified using a gel recovery and purification kit.

[0137] 4. Ligation: Use T4 DNA ligase to connect the purified and recovered RS02145 gene fragment with the pET-32a plasmid fragment.

[0138] 5. Transformation: Take 5 μL of the ligation product and add it to 50 μL of BL21 (DE3) competent cells, flick to mix, place on ice for 30 minutes, heat shock in a 42°C water bath for 45 seconds, and then quickly place on ice for 2 minutes, add 500 μL of non-resistant LB liquid medium, and culture at 37°C for 1 hour. Concentrate the bacterial solution to 100 μL and apply it to ampicillin-resistant LB solid medium, and culture at 37°C for 14 hours.

[0139] 6. Colony PCR and sequencing identification: Pick a single colony on the plate and inoculate it into LB liquid culture medium, and culture it at 37℃ for 4h. Use the bacterial solution as a template, S.tag and T7ter (sequences are shown in SEQ ID NO:25 and SEQ ID NO:26 respectively) as primers to perform colony PCR identification, and perform gel electrophoresis on the PCR product to verify the band size. The sample with a band of 1593bp is a positive sample. Figure 2 The positive strains were sent to Anhui General Biotechnology Co., Ltd. for sequencing, and the correct plasmids and corresponding bacterial solutions were selected for preservation. The correct recombinant vector pET-32a-RS02145 was constructed as shown in the schematic diagram of the vector map. Figure 8 The amino acid sequence of the recombinant protein expressed is shown in SEQ ID NO: 12, and the corresponding gene sequence is shown in SEQ ID NO: 32.

[0140] Example 7 Expression and purification of recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, rRS02145

[0141] 1. Verification of the expression of the target protein: Select the 6 positive strains constructed correctly in Examples 1 to 6 respectively and place them in 5 mL of LB liquid culture medium, culture at 37°C for 4 to 6 hours until the OD600 is 0.4, add IPTG with a final concentration of 1 mmol / L, induce at 37°C for 6 hours, concentrate the induced bacterial solution 10 times, ultrasonically lyse for 10 minutes, and centrifuge at 12000 r / min for 5 minutes to separate the supernatant of the lysate. Perform SDS-PAGE vertical electrophoresis on the separated supernatant of the lysate and the precipitate. Fig. 9 As shown, the rRS02775 recombinant protein can be expressed in the precipitate, and there is a band at the molecular weight of about 104 kDa, which is consistent with expectations; Fig.10 As shown, the rRS01455 recombinant protein can be expressed in the supernatant, and a band is present at a molecular weight of approximately 104 kDa, which is consistent with expectations; Fig.11 As shown, the rRS01745 recombinant protein was expressed in both the supernatant and the precipitate, with a band at a molecular weight of approximately 76 kDa, which was consistent with expectations; Fig.12As shown, the rRS01040 recombinant protein can be expressed in the supernatant, and a band is present at a molecular weight of approximately 119 kDa, which is consistent with expectations; Fig.13 As shown, the rRS01750 recombinant protein can be expressed in the supernatant, and a band is present at a molecular weight of about 100 kDa, which is consistent with expectations; Fig.14 As shown, the rRS02145 recombinant protein can be expressed in the supernatant, and a band is present at a molecular weight of approximately 70 kDa, which is consistent with expectations.

[0142] 2. Large-scale expression of proteins: The six positive strains constructed in Examples 1 to 6 were revived by streaking on plates, and single colonies were picked in 5 mL of LB liquid medium, and cultured at 37°C until the logarithmic growth phase. The fresh bacterial solution was transferred to 500 mL of LB liquid medium and cultured at 37°C for 4 to 6 hours until the OD600 reached 0.4. The induction conditions were as described in the previous item. The cells were collected by centrifugation at 6000 r / min for 5 minutes.

[0143] 3. Protein purification: The collected 6 kinds of bacteria were resuspended in 50mL buffer, and then ultrasonically disrupted. The purified proteins were collected using GenScript Ni-NTA affinity chromatography medium. The purified proteins were analyzed by SDS-PAGE electrophoresis. Fig.15 The purified 6 protein solutions were sterile filtered using a 0.22 μm filter membrane and stored at 4°C.

[0144] Example 8 Preparation of polyclonal antibody serum of recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, rRS02145

[0145] 1. Immunization: 6-week-old BALB / c mice were immunized with purified recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 as antigens, respectively, and the immunization method was subcutaneous multi-point injection. For the first immunization, the purified protein solution was mixed with an equal volume of Freund's complete adjuvant, and the immunization dose was 100μg of recombinant protein per mouse. Two weeks after the first immunization, the second immunization was performed, and the immunization dose was 50μg per mouse. Two weeks after the second immunization, the third immunization was performed, and the immunization dose was 100μg per mouse. The second and third immunization adjuvants were Freund's incomplete adjuvant.

[0146] 2. Serum collection: One week after the third immunization, blood was collected through the heart and placed at 37°C for 2 hours to allow serum separation. The supernatant was collected at 5000r / min for 10 minutes to obtain polyclonal antibody serum, which was stored at -20°C.

[0147] 3. Antibody titer detection: The indirect ELISA method was used to detect the polyclonal antibody titer of the recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 in the prepared antiserum. The purified recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 were diluted to a final concentration of 2 μg / mL with coating buffer (0.05 mol / L, pH 9.6 sodium carbonate-sodium bicarbonate buffer) as antigens, 2-fold serial dilutions of polyclonal antiserum as primary antibody, non-immunized BALB / c mouse serum as negative control, and HRP-labeled goat anti-mouse IgG as secondary antibody. TMB method was used for color development, and after adding the stop solution to terminate the reaction, the A450 value of each well was detected using an enzyme marker. The ratio of the A450 value of the test well to the A450 value of the negative control well was ≥2.1, which was judged as positive, and the maximum dilution that could be judged as positive was used as the antibody titer of the serum to be tested. The results showed that the titers of the antisera prepared by indirect ELISA for the recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 were 1:5120000, 1:2560000, 1:5120000, 1:10240000, 1:10240000, and 1:2560000, respectively.

[0148] Example 9 Identification of polyclonal antibody serum of recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 by Western bolt method

[0149] The whole bacterial protein of Mycoplasma synoviae Ningxia / 2017-1 strain and the purified tagged protein induced by transformation of BL21 (DE3) Escherichia coli with pET-32a empty vector were used as samples for SDS electrophoresis. The products after electrophoresis were transferred to nitrocellulose membrane (NC membrane), and Western bolt identification was performed using 500-fold dilutions of the six antisera prepared in Example 8 as primary antibodies and HRP-labeled goat anti-mouse IgG as secondary antibodies. The results of serum identification of recombinant protein rRS02775 polyclonal antibody are shown in Figure 2. Fig.16 As shown in the figure, the polyclonal antibody prepared can specifically bind to Mycoplasma synoviae, and there is a band at the molecular weight of about 84kDa, which is consistent with expectations. Fig.17 As shown in the figure, the polyclonal antibody prepared can bind to Mycoplasma synoviae, and there is a band at the molecular weight of about 84kDa, which is consistent with expectations. Fig.18 As shown in the figure, the prepared polyclonal antibody can specifically bind to Mycoplasma synoviae, and there is a band at the molecular weight of about 56Da, which is consistent with expectations. Fig.19 As shown in the figure, the prepared polyclonal antibody can specifically bind to Mycoplasma synoviae, and there is a band at the molecular weight of about 99kDa, which is consistent with expectations. Fig. 20 As shown in the figure, the prepared polyclonal antibody can specifically bind to Mycoplasma synoviae, and there is a band at the molecular weight of about 80kDa, which is consistent with expectations. Fig.21 As shown, the prepared polyclonal antibody can specifically bind to Mycoplasma synoviae, and a band is present at the molecular weight of about 50 kDa, which is consistent with expectations.

[0150] Example 10 Neutralization titer determination of specific polyclonal antibodies against recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145

[0151] Add 100 μL of the diluted polyclonal serum prepared in Example 9 to each well in the first column of a 96-well round-bottom deep-well plate, the dilution factor is 16 times, and the diluent is a liquid culture medium for Mycoplasma synoviae (Mycoplasma Broth Base 25.5 g / L, glucose 3.3 g / L, coenzyme 100 mg / L, arginine 400 mg / L, cysteine ​​100 mg / L, phenol red 0.02%, porcine serum 15%, pH 7.8), and then make a 2-fold dilution in each column, and set 8 dilutions for each serum. Add 200 μL of liquid culture medium for Mycoplasma synoviae to each well in the 9th column as a negative control, and add 100 μL of liquid culture medium for Mycoplasma synoviae to the 10th column as a positive control. Add 10 CCU to each well in columns 1-8 and 10 4CCU / ml of Mycoplasma synoviae bacterial liquid. Cover with the matching silicone cover to complete the seal, incubate in a 37°C biochemical incubator until the positive control color changes, and use the serum dilution gradient of the critical well where the color does not change as the neutralization titer. The results showed that the recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 specific polysera all had neutralizing effects on Mycoplasma synoviae WVU1853 strain, Ningxia / 2017-1 strain, and Shandong / 2017-2 strain (ZHANG X, CHEN Y, XIE D, et al. Multi-locus sequence typing analysis of Mycoplasma synoviae isolates reveals unique sequence types in China[J]. Veterinary microbiology, 2021, 259(109101.), and the neutralization titers are shown in Table 7:

[0152] Table 7 Neutralization titer of recombinant protein polyclonal antibody

[0153]

[0154] Example 11: Single protein preparation of subunit vaccine immune challenge protection test

[0155] 1. Preparation of subunit vaccine: The six recombinant proteins purified in step 4 of Example 7 were diluted with physiological saline to a protein concentration of 555.6 μg / mL, and then the diluted protein solution was evenly mixed with aluminum hydroxide gel adjuvant at a ratio of 3:1 to prepare a subunit vaccine. Aluminum hydroxide gel adjuvant was purchased from Thermo Fisher Scientific, catalog number: 77161.

[0156] 2. Immunization: 10 21-day-old SPF chickens were immunized with the prepared subunit vaccine by intramuscular injection in the chest. The immunization dose was 0.12 mL per chicken. Ten challenge control chickens and 10 blank control chickens were set up. A second immunization was performed with the same dose 21 days after the second immunization. About 10 live bacteria were used for the experimental chickens in each immunization group and the challenge control group 21 days after the second immunization. 7 The chickens were challenged by injecting 0.1 ml of bacterial solution at CCU / mL into the paw pads. The disease occurrence of the test chickens was observed within 21 days.

[0157] Statistics of immune protection efficacy results: The paw pad lesions were scored according to the following criteria: 0 points for no obvious swelling or lesions on the paw pad; 1 point for mild swelling or lesions and thickening of the paw pad; 2 points for obvious swelling of the paw pad and tissue hyperplasia seen during autopsy; 3 points for obvious swelling of the paw pad, mild deformation of the foot, obvious tissue hyperplasia and granulomas seen during autopsy, and a small amount of purulent exudate; 4 points for severe swelling of the paw pad, severe deformation of the foot, obvious tissue hyperplasia seen during autopsy, a large number of granulomas, and a large amount of purulent exudate. The scoring criteria for joint lesions were as follows: 0 points for no obvious swelling or lesions in the joints; 1 point for mild swelling or lesions in the joints with exudation; 2 points for obvious swelling in the joints and tissue hyperplasia on autopsy; 3 points for obvious swelling in the joints, mild deformation of the foot, obvious tissue hyperplasia and granulomas on autopsy, and a small amount of purulent exudate; 4 points for severe swelling or deformation in the joints, obvious tissue hyperplasia on autopsy, a large number of granulomas, and a large amount of purulent exudate. Fig. 22 As shown in Table 8, the average lesion scores of joints and paw pads in each immunization group were lower than those in the challenge control group. The data were analyzed by one-way analysis of variance. The joint lesion scores of rRS02775 immunization group, rRS01455 immunization group, rRS01745 immunization group, rRS01040 immunization group, and rRS01750 immunization group were significantly lower (P<0.05) than those in the challenge control group. The paw pad lesion scores of the rRS02775 immunization group and the rRS01750 immunization group were significantly lower (P<0.05) than those in the challenge control group. The incidence of each experimental group is shown in Table 8. The incidence of paw pad swelling and tarsal synovitis in each protein immunization group were lower than those in the challenge control group. The results showed that recombinant proteins rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, and rRS02145 could reduce the incidence of chicken paw swelling and tarsal joint synovitis after immunization, and at the same time significantly alleviate the severity of lesions, showing a good immune protection effect.

[0158] Table 8 Incidence rate of each group in the immune protection efficacy test of subunit vaccine prepared by single protein

[0159]

[0160] Example 12: Multi-protein combination to prepare subunit vaccine immune challenge protection test

[0161] 1. Preparation of subunit vaccine: The 6 recombinant proteins purified in step 4 of Example 7 were mixed and diluted with physiological saline to a total protein concentration of 666.6 μg / mL, wherein the concentration of each recombinant protein was 111.1 μg / mL, and then the mixed protein solution was evenly mixed with aluminum hydroxide gel adjuvant at a ratio of 3:1 to prepare a subunit vaccine. Aluminum hydroxide gel adjuvant was purchased from Thermo Fisher Scientific, catalog number: 77161.

[0162] 2. Immunization: Take 50 SPF chickens aged 21 days and randomly divide them into 5 groups, 10 in each group. Subunit vaccine group: Immunize with the prepared subunit vaccine by intramuscular injection in the chest, with an immunization dose of 0.12 ml per chicken. A second immunization will be performed 21 days after the second immunization with the same dose. Synovial Mycoplasma inactivated vaccine group: Immunize with chicken synoviae Mycoplasma inactivated vaccine (YBF-MS1 strain) (purchased from Qingdao Bioengineering Co., Ltd.) by intramuscular injection in the chest, with an immunization dose of 0.5 ml per chicken. A second immunization will be performed 21 days after the second immunization with the same dose. MS-H temperature-sensitive live vaccine group: Immunize with MS-H temperature-sensitive live vaccine (purchased from Australian Bioresources Company) at a dose of 30 μL / bird. The attack control group and the blank control group were not immunized. When the experimental chickens were 63 days old, all groups of experimental chickens except the blank control group were treated with about 10 live bacteria. 7 The chickens were challenged by injecting 0.1 mL of bacterial solution at CCU / mL into the paw pads. The disease occurrence of the test chickens was observed within 21 days.

[0163] 3. Statistics of immune protection efficacy: The scoring criteria for the lesions of the paw pads and joints were consistent with those in Example 11. Fig.23 As shown in Table 9, the average lesion scores of joints and paw pads in each immunization group were lower than those in the challenge control group. The data were analyzed for significance by one-way analysis of variance. The paw pad and joint lesion scores of the subunit vaccine immunization group were significantly different from those of the challenge control group (P<0.01). The paw pad and joint lesion scores of the inactivated vaccine immunization group were not significantly different from those of the challenge control group. The paw pad lesion score of the MS-H immunization group was significantly different from that of the challenge control group (P<0.01), and the joint lesion score was significantly different from that of the challenge control group (P<0.05). The incidence of each experimental group is shown in Table 9. The incidence of paw pad swelling and tarsal synovitis in the subunit vaccine immunization group was 2 / 10, the incidence of paw pad swelling and tarsal synovitis in the MS-H live vaccine immunization group was 3 / 10, the incidence of paw pad swelling in the inactivated vaccine immunization group was 5 / 10, and the incidence of tarsal synovitis was 3 / 10.

[0164] Table 9 Incidence rate of each group in the immune protection efficacy test of subunit vaccines prepared by multi-protein combination

[0165]

[0166] from Fig.24 It can be seen that this subunit vaccine can significantly reduce the severity of chicken paw pad lesions and the incidence of tarsal joint synovitis after immunization, and has a good immune protection effect.

Claims

1. A recombinant chicken synoviae Mycoplasma antigen protein, characterized in that: The recombinant chicken synoviae Mycoplasma antigen protein is selected from the following proteins (a), (b) or (c): (a) a protein having an amino acid sequence as shown in SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, or SEQ ID NO:38; (b) a protein derived from (a) having the activity of an antigenic protein of Mycoplasma synoviae, wherein the amino acid sequence in (a) is substituted, deleted or added with one or more amino acids; (c) A protein having an amino acid sequence as shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:

12.

2. The nucleic acid or gene encoding the recombinant chicken synoviae Mycoplasma antigen protein according to claim 1, characterized in that: The nucleic acid or gene is selected from the following genes or nucleic acids (i), (ii) or (iii): (i) a gene or nucleic acid whose nucleotide sequence is shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11; (ii) a gene or nucleic acid having the activity of encoding an antigenic protein of Mycoplasma synoviae in which the nucleotide sequence in (i) is substituted, deleted or added with one or several bases; (iii) a gene or nucleic acid having a nucleotide sequence as shown in SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 or SEQ ID NO:

32.

3. An expression cassette, a recombinant vector or a recombinant bacterium, characterized in that: It contains the nucleic acid or gene according to claim 2.

4. The recombinant vector according to claim 3, characterized in that The recombinant vector is obtained by inserting the nucleic acid or gene according to claim 2 into a vector. Preferably, the nucleic acid or gene is inserted between the T7 terminator sequence and the lac operator sequence of the vector.

5. The recombinant vector according to claim 4, characterized in that The vector includes a prokaryotic expression vector.

6. The method for preparing the recombinant chicken synoviae Mycoplasma antigen protein according to claim 1, characterized in that: The following steps are involved: 1) Obtaining the nucleic acid or gene according to claim 2; 2) introducing the nucleic acid or gene obtained in step 1) into a vector to obtain a recombinant vector; 3) The recombinant vector is introduced into the host bacteria to induce expression to obtain the recombinant chicken synoviae Mycoplasma antigen protein.

7. Use of the recombinant Mycoplasma synoviae antigen protein according to claim 1, the nucleic acid or gene according to claim 2, the expression cassette, recombinant vector or recombinant bacteria according to claim 3 in the preparation of a drug, polyclonal antibody or vaccine for treating or preventing Mycoplasma synoviae infection.

8. A polyclonal antibody, characterized in that The polyclonal antibody is obtained by immunizing an animal with the recombinant chicken synoviae Mycoplasma antigen protein according to claim 1.

9. A vaccine, characterized in that The vaccine comprises the recombinant chicken synoviae Mycoplasma antigen protein according to claim 1.

10. The vaccine according to claim 9, characterized in that The vaccine also includes an adjuvant.

Citation Information

Patent Citations

  • Expression vector and fused protein of human differential initiator 3 and preparation thereof

    CN101275147A

  • Vascular targeting soluble fusion protein TrxHis-hDlll-RGD

    CN101891824A

  • Mycoplasma synoviae antigen protein LP85, ELISA detection method of corresponding antibody and kit

    CN112538106A

  • Chicken mycoplasma synoviae subunit vaccine as well as preparation method and application thereof

    CN114045298A

  • Rationally designed mycoplasma gallisepticum subunit vaccine

    WO2024118234A2

Cited By

  • Recombinant chicken mycoplasma synoviae antigen protein as well as coding gene, preparation method and application thereof

    CN120607596A